Abstract
Diabetic macular edema (DME) represents the most common cause of vision loss in patients affected by diabetes mellitus. Although the pathophysiology of DME is not wholly understood, vascular endothelial growth factor (VEGF) has been identified as a key contributor to the development of DME. In addition, latest information suggests that acute and chronic inflammatory changes occur, contributing to the DME pathogenesis. The current therapeutic approach for DME is mainly based on the administration of anti-VEGF molecules. In particular, VEGF-inhibitors that have been studied for diabetic retinopathy include pegaptanib, ranibizumab, bevacizumab, and aflibercept. The present review analyzes the main characteristics of each molecule, describing the most important results of clinical trails.
Keywords: Diabetic retinopathy, diabetic macular edema, anti-vascular endothelial growth factor.
Current Pharmaceutical Design
Title:Anti-VEGF Molecules for the Management of Diabetic Macular Edema
Volume: 21 Issue: 32
Author(s): Francesco Bandello, Maria Vittoria Cicinelli and Maurizio Battaglia Parodi
Affiliation:
Keywords: Diabetic retinopathy, diabetic macular edema, anti-vascular endothelial growth factor.
Abstract: Diabetic macular edema (DME) represents the most common cause of vision loss in patients affected by diabetes mellitus. Although the pathophysiology of DME is not wholly understood, vascular endothelial growth factor (VEGF) has been identified as a key contributor to the development of DME. In addition, latest information suggests that acute and chronic inflammatory changes occur, contributing to the DME pathogenesis. The current therapeutic approach for DME is mainly based on the administration of anti-VEGF molecules. In particular, VEGF-inhibitors that have been studied for diabetic retinopathy include pegaptanib, ranibizumab, bevacizumab, and aflibercept. The present review analyzes the main characteristics of each molecule, describing the most important results of clinical trails.
Export Options
About this article
Cite this article as:
Bandello Francesco, Cicinelli Vittoria Maria and Parodi Battaglia Maurizio, Anti-VEGF Molecules for the Management of Diabetic Macular Edema, Current Pharmaceutical Design 2015; 21 (32) . https://dx.doi.org/10.2174/1381612821666150909095756
DOI https://dx.doi.org/10.2174/1381612821666150909095756 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Impact of Oncogenic Protein Tyrosine Phosphatases in Cancer
Anti-Cancer Agents in Medicinal Chemistry Angiogenesis as a Therapeutic Target in Arthritis: Lessons from Oncology
Current Pharmaceutical Design Intestinal Immunomodulation. Role of Regulative Peptides and Promising Pharmacological Activities
Current Pharmaceutical Design Animal Models for Growth Hormone Gene Therapy
Current Gene Therapy Optical Image-Guided Cancer Therapy
Current Pharmaceutical Biotechnology Editorial: Role of Cancer Stem Cells in Common Gastrointestinal Cancers: From Pathogenesis to Therapeutic Targets
Current Stem Cell Research & Therapy The Synthesis of Nano-Doxorubicin and its Anticancer Effect
Anti-Cancer Agents in Medicinal Chemistry EGFR-Targeting Monoclonal Antibodies in Head and Neck Cancer
Current Cancer Drug Targets Cancer Pharmacogenetics: The Move from Pharmacokinetics to Pharmacodynamics
Current Pharmacogenomics NUPR1 Interacts with p53, Transcriptionally Regulates p21 and Rescues Breast Epithelial Cells from Doxorubicin-Induced Genotoxic Stress
Current Cancer Drug Targets Antioxidant Constituents from the Stem and Leaf of Helicteres hirsuta Loureiro
The Natural Products Journal Update on COX-2 Selective Inhibitors: Chemical Classification, Side Effects and their Use in Cancers and Neuronal Diseases
Current Topics in Medicinal Chemistry Tumor Targeted Therapies: Strategies for Killing Cancer but not Normal Cells
Current Cancer Therapy Reviews The Therapeutic Potential of the Wnt Signaling Pathway in Bone Disorders
Current Molecular Pharmacology A Brief Review of circRNA Biogenesis, Detection, and Function
Current Genomics Anticancer Drugs in Liposomal Nanodevices: A Target Delivery for a Targeted Therapy
Current Topics in Medicinal Chemistry Anti-Hormonal Therapies for Premenopausal Patients – What did we Learn from the TEXT/SOFT Trials?
Reviews on Recent Clinical Trials Prediction of Michaelis-Menten Constant of Beta-Glucosidases Using Nitrophenyl-beta-D-Glucopyranoside as Substrate
Protein & Peptide Letters Sorafenib (BAY 43-9006): Review of Clinical Development
Current Clinical Pharmacology Apoptosis Signalling Activated by TNF in the Lower Gastrointestinal Tract-Review
Current Pharmaceutical Biotechnology